SCHEMBL11926366

SCHEMBL11926366

Nc1cccc(NC(=O)c2cc(OCCN3CCOCC3)nc(N3CCOCC3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.46
PTPN11 Q06124 1/20 0.44
KDR P35968 3/20 0.44
RXFP1 Q9HBX9 1/20 0.43
EPHX2 P34913 5/20 0.43
EGFR P00533 2/20 0.43
AURKB Q96GD4 2/20 0.42
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
ROCK2 O75116 1/20 0.42
RPS6KA5 O75582 1/20 0.42
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
LCK P06239 1/20 0.42
PIM1 P11309 1/20 0.42
PRKACA P17612 1/20 0.42
RPS6KB1 P23443 1/20 0.42
CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11926380 0.92 SETD2 (0.47) GRM4KDRRXFP1EPHX2AURKB
SCHEMBL11926374 0.90 KDM4E (0.51) GRM4KDREPHX2AURKBAKT1
SCHEMBL427105 0.90 KDR (0.52) GRM4KDRRXFP1EPHX2AURKB
SCHEMBL11926367 0.90 SETD2 (0.45) GRM4KDRRXFP1EPHX2AURKB
SCHEMBL423803 0.90 KDR (0.46) GRM4KDRRXFP1EPHX2AURKB
SCHEMBL430651 0.89 TSHR (0.56) GRM4KDRAKT1FLT3TSHR
SCHEMBL11926369 0.89 GRM4 (0.47) GRM4KDRRXFP1EPHX2EGFR
SCHEMBL428647 0.89 ALDH1A1 (0.50) GRM4KDRRXFP1EPHX2EGFR
SCHEMBL11926304 0.89 KDR (0.47) GRM4KDREPHX2KCNH2
SCHEMBL423976 0.88 SCN10A (0.51) GRM4KDREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 US disclosed
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG GRM4 1556/4885PTPN11 672/4885KDR 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.